journal article·2022-12-31Open access

Enhanced anti-cancer effect using MMP-responsive L-asparaginase fused with cell-penetrating 30Kc19 protein

Jina Ryu, Sung Jae Yang, Boram Son, Haein Lee, Jongmin Lee, Jinmyoung Joo, Hee Ho Park, Tai Hyun Park

Abstract

As the acute lymphoblastic leukaemia (ALL) develops, expression of L-asparaginase (ASNase) protein is known to decrease. Therefore, deficiency of the ASNase protein would be regarded as one of the significant indications of the ALL. For the treatment of ALL, recombinant ASNase protein derived from bacterial origin is used which causes cytotoxicity by deprivation of Asn. However, short half-life of the protein is an obstacle for medical use. In order to overcome this limit, recombinant ASNase was fused to 30Kc19 with protein-stabilizing and cell-penetrating properties. As the 30Kc19 protein may induce steric hindrance, we further added a PLGLAG linker sequence (LK) between the ASNase and 30Kc19. The treatment of ASNase-LK-30Kc19 fusion protein demonstrated enhanced stability, cell-penetrating property, and anti-cancer activity. Intracellular delivery of both the non-cleaved and cleaved forms of the protein were observed, suggesting that ASNase acted both internally and externally, performing high anti-cancer activity by effective depletion of intracellular Asn. Additionally, ASNase-LK-30Kc19 showed high selectivity towards cancer cells. In terms of the dosage, releasable ASNase from ASNase-LK-30Kc19 reached the same half-maximal inhibitory concentration at a concentration five times lower than non-releasable ASNase-30Kc19. Altogether, the findings suggest that this fusion approach has potential applications in the treatment of ALL.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Acute Lymphoblastic Leukemia research · Biochemical and Molecular Research · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Republic of Korea

School of Chemical and Biological Engineering, Institute of Chemical Processes, Seoul National University, Seoul, Republic of Korea

Department of Bioengineering, Hanyang University, Seoul, Republic of Korea

Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea

Education and Research Group for Biopharmaceutical Innovation Leader, Hanyang University, Seoul, Republic of Korea

BioMAX/N-Bio Institute, Institute of Bioengineering, Seoul National University, Seoul, Republic of Korea

Funding

National Research Foundation of Korea · the Korea government

References (49)

Show source-provided references
1. 10.1186/s40164-020-00170-610.1186/s40164-020-00170-6 ↗
2. 10.1038/sj.leu.240178010.1038/sj.leu.2401780 ↗
3. 10.2147/DIJN.1.S62310.2147/DIJN.1.S623 ↗
4. 10.1016/S0022-3476(82)80535-010.1016/S0022-3476(82)80535-0 ↗
5. 10.3389/fbioe.2018.0021210.3389/fbioe.2018.00212 ↗
6. 10.1016/S0958-1669(99)00003-810.1016/S0958-1669(99)00003-8 ↗
7. 10.1182/blood.V110.11.4325.432510.1182/blood.V110.11.4325.4325 ↗
8. 10.1634/theoncologist.12-8-99110.1634/theoncologist.12-8-991 ↗
9. 10.1182/blood-2006-09-04535110.1182/blood-2006-09-045351 ↗
10. 10.1007/s13346-013-0176-510.1007/s13346-013-0176-5 ↗
11. 10.1016/j.procbio.2016.09.02910.1016/j.procbio.2016.09.029 ↗
12. 10.1023/A:102112561782810.1023/A:1021125617828 ↗
13. 10.1186/1556-276X-9-34010.1186/1556-276X-9-340 ↗
14. 10.1182/blood.V122.21.2669.266910.1182/blood.V122.21.2669.2669 ↗
15. 10.1007/s10856-008-3684-y10.1007/s10856-008-3684-y ↗
16. 10.1002/bit.2102310.1002/bit.21023 ↗
17. 10.1002/bit.2055010.1002/bit.20550 ↗
18. 10.1021/bp020001q10.1021/bp020001q ↗
19. 10.1023/A:101848430919410.1023/A:1018484309194 ↗
20. 10.1007/BF0017422310.1007/BF00174223 ↗
21. 10.1007/BF0294026010.1007/BF02940260 ↗
22. 10.1021/bp034130y10.1021/bp034130y ↗
23. 10.1021/bp990093s10.1021/bp990093s ↗
24. 10.1016/S0006-291X(02)00746-510.1016/S0006-291X(02)00746-5 ↗
25. 10.1006/bbrc.2000.259210.1006/bbrc.2000.2592 ↗
26. 10.1016/j.biomaterials.2013.11.00110.1016/j.biomaterials.2013.11.001 ↗
27. 10.1007/s00253-016-7689-z10.1007/s00253-016-7689-z ↗
28. 10.1016/j.biomaterials.2012.08.06310.1016/j.biomaterials.2012.08.063 ↗
29. 10.1002/biot.20160004010.1002/biot.201600040 ↗
30. 10.1080/21691401.2016.120005910.1080/21691401.2016.1200059 ↗
31. 10.1016/j.procbio.2014.05.00810.1016/j.procbio.2014.05.008 ↗
32. 10.1016/j.procbio.2015.03.00810.1016/j.procbio.2015.03.008 ↗
33. 10.1007/s00253-014-6045-410.1007/s00253-014-6045-4 ↗
34. 10.1007/s00253-015-7199-410.1007/s00253-015-7199-4 ↗
35. 10.1002/bit.2309110.1002/bit.23091 ↗
36. 10.1039/b904878b10.1039/b904878b ↗
37. 10.1039/b904890a10.1039/b904890a ↗
38. 10.1016/j.jconrel.2012.02.00710.1016/j.jconrel.2012.02.007 ↗
39. Lee J. Stabilization and red blood cell encapsulation of L-asparaginase by fusion with 30Kc19 protein [master’s thesis]. Seoul National University Seoul; 2013.
40. 10.1099/00221287-76-1-8510.1099/00221287-76-1-85 ↗
41. 10.1016/S0076-6879(85)13082-X10.1016/S0076-6879(85)13082-X ↗
42. Chen X Zaro JL Shen WC. Fusion protein linkers: property design and functionality. Adv Drug Deliv Rev.2013; 65(10):1357–1369.10.1016/j.addr.2012.09.039 ↗
43. 10.1098/rsob.13012110.1098/rsob.130121 ↗
44. 10.1039/C8CS00676H10.1039/C8CS00676H ↗
45. 10.1039/D0CB00114G10.1039/D0CB00114G ↗
46. 10.1073/pnas.091028310710.1073/pnas.0910283107 ↗
47. 10.1002/jcp.2404010.1002/jcp.24040 ↗
48. 10.1038/cddiscovery.2017.3610.1038/cddiscovery.2017.36 ↗
49. 10.1021/acs.molpharmaceut.5b0070610.1021/acs.molpharmaceut.5b00706 ↗